Bluebird Bio announces first patient transplanted in Phase 1/2 Northstar study bluebird bio announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study -- HGB-204 -- in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. The phase 1/2 study is designed to evaluate the feasibility, safety and efficacy of LentiGlobin drug product in the treatment of subjects with beta-thalassemia major. The study is designed to enroll up to fifteen subjects. Subjects will be evaluated for safety and efficacy post-transplant.
bluebird bio price target raised to $119 from $112 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio to $119 following the company's Q4 results and reiterates an Overweight rating on the name. Piper sees 2015 as a "big year" for bluebird with preliminary sickle cell data.